Clinical trials: Neck Lines
Esophageal Cancer
Phase II Study of Irinotecan and Panitumumab
This study proposes a single-arm, phase II study of irinotecan with panitumumab as second-line therapy for patients with advanced esophageal adenocarcinoma.
- Trial name
- NCT00836277
- Testing
- Panitumumab, Irinotecan
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Weijing Sun, MD, FACP
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Cetuximab Plus Dalpicilib in Patients With HPV Negative, PD-1 Resistant R/M HNSCC
This study is the first clinical study in PD-1 resistant patients with head and neck squamous cell carcinoma with drugs targeting EGFR signaling pathway combined with CDK4/6 inhibitors, which explores the new combination…
- Trial name
- NCT05721443
- Testing
- Dalpiciclib+cetuximab
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Metastatic Esophageal Squamous Cell Carcinoma
Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.
This study is a multi-center, non-interventional study. Clinicopathologic, treatment , outcome and efficacy data will be collected from medical records in metastatic esophageal squamous cell carcinoma (ESCC) patients.
- Trial name
- REICRAE (NCT06190652)
- Testing
- Chemotherapy combined with immunotherapy, radiotherapy
- Where
- 5 sites in China
- Volunteers
- 728 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Tongue Neoplasms, Carcinoma
Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line
In vitro study to examine whether luteolin and nano-luteolin exert an inhibitory effect on tongue squamous cell carcinoma cell line by inducing apoptosis, and to assess if nano-luteolin has more efficient apoptotic activity than…
- Trial name
- NCT03288298
- Testing
- luteolin, nano-luteolin
- Volunteers
- 4 people
- Sponsor
- Cairo University
Esophageal Carcinoma
Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)
GLOBOCAN 2020 reported that the global incidence of esophageal cancer climbed to 604,100, accounting for 3.1% of all tumor sites and ranking 7th out of 36 cancers.
- Trial name
- CAR-RMEC (NCT06681285)
- Testing
- Cadonilimab ;Anlotinib
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Hebei Medical University Fourth Hospital
Cervical Cancer
A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
This study was an randomized, double-Blind, placebo-controlled, multicenter Phase II/III study.
- Trial name
- NCT06755515
- Testing
- Rulonilimab, cisplatin/carboplatin + paclitaxel ± bevacizumab
- Where
- China
- Volunteers
- 510 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer
Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
This is a global, multi-center, Phase 3 study that is randomized 1:1, controlled, and open label to evaluate PDS0101 (Versamune + HPVMix) in combination with pembrolizumab vs.
- Conditions
- Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck
- Trial name
- VERSATILE-003 (NCT06790966)
- Testing
- Combination Treatment of PDS0101 and Pembrolizumab, Pembrolizumab Monotherapy
- Where
- 28 sites in United States
- Volunteers
- 12 people
- Sponsor
- PDS Biotechnology Corp.
METASTATIC CERVICAL CANCER
QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
This study is a randomized, double-blind, placebo-controlled, multicenter phase III clinical study in 498 patients with persistent, recurrent or metastatic cervical cancer.Experimental: QL1706 + Chemotherapy…
- Trial name
- NCT05446883
- Testing
- QL1706, Paclitaxel injection, Cisplatin/Carboplatin
- Where
- 3 sites in China
- Volunteers
- 498 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Metastatic Nasopharyngeal Carcinoma
Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment
to evaluate the efficacy and safety of toripalimab and capecitabine maintenance therapy in patients with metastatic nasopharyngeal carcinoma (NPC) after first-line gemcitabine/cisplatin combined with toripalimab.
- Trial name
- NCT05484375
- Testing
- Capecitabine plus toripalimab
- Volunteers
- 40 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
In this study, patients with recurrent or metastatic head and neck squamous cell carcinoma will receive first line treatment with olaparib, pembrolizumab, and carboplatin.
- Trial name
- NCT04643379
- Testing
- Olaparib, Pembrolizumab, Carboplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Washington University School of Medicine
Head and Neck Cancer
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to evaluate the safety and efficacy of the combination of retifanlimab plus INCAGN02385 and retifanlimab plus INCAGN02385 and INCAGN02390 compared with retifanlimab alone as first-line treatment in…
- Trial name
- NCT05287113
- Testing
- Retifanlimab, INCAGN02385, INCAGN02390
- Where
- 91 sites in United States, Belgium and 12 more
- Volunteers
- 176 people
- Sponsor
- Incyte Biosciences International Sàrl
Esophageal Cancer, Esophageal Squamous Cell Carcinoma
A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
This is a randomized, open-label study to compare how well LBL-007 works in combination with tislelizumab and chemotherapy versus tislelizumab and chemotherapy when given as the first-line treatment in participants with…
- Conditions
- Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma by AJCC V8 Stage
- Trial name
- NCT06010303
- Testing
- LBL-007, Tislelizumab, Chemotherapy Doublet
- Where
- 38 sites in China, South Korea and 2 more
- Volunteers
- 118 people
- Sponsor
- BeiGene
Squamous Cell Carcinoma of the Head and Neck Cancer
EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to determine if EMD 1201081 in combination with cetuximab is more efficient than cetuximab alone to control the cancer.
- Trial name
- NCT01040832
- Testing
- Cetuximab, EMD 1201081
- Where
- 35 sites in United States, Belgium and 6 more
- Volunteers
- 107 people
- Sponsor
- EMD Serono
Neoplasms, Solid Tumors
An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy
The goal of this clinical trial is to learn if Zanidatamab can treat HER2-positive advanced tumors in adults. The main question it aims to answer is: What is the objective response rate of Zanidatamab in adult patients with HER-2…
- Conditions
- Neoplasms, Solid Tumors, HER2 Positive Solid Tumor, Endometrial Neoplasm
- Trial name
- NCT07631871
- Testing
- Zanidatamab
- Volunteers
- 10 people
- Sponsor
- Haihua Yuan
Esophageal Cancer
Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.
To assess the efficacy and safety of adebrelimab in combination with apatinib mesylate and chemoradiotherapy in immuno-experienced second-line esophageal squamous cell carcinoma (with symptomatic dysphagia or oligometastatic…
- Trial name
- NCT06464614
- Testing
- Adebrelimab, Apatinib, Investigator chosen chemotherapy (ICC)
- Where
- China
- Volunteers
- 54 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Head and Neck Squamous Cell Carcinoma
AK117 (Anti-CD47 mAb) Plus Cetuximab as Second-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
The administration of first-line pembrolizumab monotherapy or combined chemotherapy has been shown to improve survival among patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
- Trial name
- NCT06508606
- Testing
- AK117 + Cetuximab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- West China Hospital
Locally Advanced Head and Neck Squamous Cell Carcinoma
Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC
First-line treatment of locally advanced HNSCC with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T cell Infiltration.
- Trial name
- NCT03426657
- Testing
- Durvalumab + Tremelimumab + RT
- Where
- 7 sites in Germany
- Volunteers
- 120 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Head and Neck Squamous Cell Carcinoma, Metastases
Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC)
To evaluate the safety and efficacy of combination of Sintilimab and SBRT on the basis of platinum-containing chemotherapy as the first-line treatment of limited metastatic head and neck squamous cell carcinoma (LM-HNSCC).
- Conditions
- Head and Neck Squamous Cell Carcinoma, Metastases, Immunotherapy, Stereotactic Body Radiotherapy
- Trial name
- LM-HNSCC (NCT05136768)
- Testing
- Sintilimab, SBRT, Platinum based chemotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Jun-Lin Yi, MD
Advanced Cervical Cancer
Combination Therapy for First Line Treatment of Advanced Cervical Cancer
This is a single center phase 1 trail to observe safety and efficacy of Paclitaxel plus Cisplatin\Carboplatin, PD-L1 antibody Toripalimab and Anlotinib as first-line regimen to treat the patient with metastatic 、persistent or…
- Trial name
- NCT04731038
- Testing
- Anlotinib, Toripalimab, Paclitaxel, Cisplatin/ Carboplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Cervical Cancer
A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
This is A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate AK104 Plus Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical…
- Trial name
- NCT04982237
- Testing
- AK104, paclitaxel, carboplatin
- Where
- 5 sites in China
- Volunteers
- 445 people
- Sponsor
- Akeso